982 / 1084
First line
Doublets or triplets?
Triplets only in patients with
high symptom burden
Stop using epirubicin
Second line
What should be a standard?
Molecular classification
Do we have distinct treatment choices for
these different molecular pathways?
How can we address tumor heterogenity
when we design GC clinical trials?
Are all patients candidated to a second line therapy?
03/28/2017